Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.
Ou YamaguchiKyoichi KairaTomonori KawasakiAtsuto MouriKosuke HashimotoAyako ShionoShun ShinomiyaYu MiuraFuyumi NishiharaYoshitake MurayamaKunihiko KobayashiSatoshi MochidaHiroshi KagamuPublished in: Thoracic cancer (2020)
The use of osimertinib immediately after nivolumab significantly increased the frequency of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboring EGFR mutation acquired T790M resistance.